Core Viewpoint - The stock of Baiaosaitu-B (02315) has increased over 12% and approximately 30% in the last three days, indicating strong market interest and positive sentiment towards the company's developments [1] Group 1: Company Developments - Baiaosaitu has completed the localization deployment of its AI-driven antibody drug research platform, which is now fully integrated with its core business, the "Thousand Mice and Ten Thousand Antibodies" program [1] - The company is building an AI intelligence system for antibody drug development, which aims to provide global pharmaceutical companies with more efficient research tools and a richer library of antibody molecules [1] - The ongoing integration of the "Thousand Mice and Ten Thousand Antibodies" program with the AI system is expected to enhance the efficiency of preclinical PCC molecule development for pharmaceutical partners, marking a new phase in antibody discovery business [1] Group 2: Strategic Partnerships - Baiaosaitu has entered into an option and licensing agreement with Yushibo to systematically evaluate the BsADC (bispecific antibody-drug conjugate) project through a structured assessment mechanism [1] - This partnership aims to accelerate the development process of BsAD2C (bispecific antibody dual drug conjugate) [1]
港股异动 | 百奥赛图-B(02315)再涨超12% 公司已完成AI驱动抗体药物研发平台的本地化部署